Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis (Q46925588)

26 December 2017

title

Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis (English)

1 reference

26 December 2017

experimental autoimmune encephalomyelitis

main subject

0 references

author name string

K M Mitchell

1

1 reference

26 December 2017

A L Dotson

2

1 reference

26 December 2017

K M Cool

3

1 reference

26 December 2017

A Chakrabarty

4

1 reference

26 December 2017

S H Benedict

5

1 reference

26 December 2017

S M LeVine

6

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Multiple Sclerosis Journal

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 December 2017

volume

13

1 reference

26 December 2017

issue

9

1 reference

26 December 2017

page(s)

1118-1126

1 reference

26 December 2017

Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Iron toxicity and chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales' disease: direct evidence using electron spin resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The lysosomal-mitochondrial axis theory of postmitotic aging and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Desferrioxamine in chronic progressive multiple sclerosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Quantifying immunohistochemical staining of phospho-eIF2alpha, heme oxygenase-2 and NADPH cytochrome P450 reductase in oligodendrocytes during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Effects of deferiprone on immune status and cytokine pattern in thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Iron deposits in multiple sclerosis and Alzheimer's disease brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Signal intensity on MRI of basal ganglia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Differential inhibition of inducible T cell cytokine secretion by potent iron chelators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Iron chelators induce apoptosis in proliferating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

A multi-center safety trial of the oral iron chelator deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Cortical lesions and brain atrophy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Secondary progressive multiple sclerosis: current knowledge and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Oxidative stress induces axonal beading in cultured human brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507078916

21 January 2018

Identifiers

DOI

10.1177/1352458507078916

1 reference

26 December 2017

release_jsm7vclatrfodguckp2mvplori

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jsm7vclatrfodguckp2mvplori

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

17967839

1 reference

26 December 2017